- Trials with a EudraCT protocol (57)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
57 result(s) found for: Primary Central Nervous System Lymphoma.
Displaying page 1 of 3.
EudraCT Number: 2009-014722-42 | Sponsor Protocol Number: HO105 | Start Date*: 2010-07-07 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup study | |||||||||||||
Medical condition: Primary Central Nervous system Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004772-12 | Sponsor Protocol Number: NLGPCNSL | Start Date*: 2006-12-19 | |||||||||||
Sponsor Name:Nordic Lymphoma Group | |||||||||||||
Full Title: Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by... | |||||||||||||
Medical condition: Newly diagnosed Primary Central Nervous Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006234-39 | Sponsor Protocol Number: GB5121-2101 | Start Date*: 2022-12-09 | ||||||||||||||||
Sponsor Name:GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | ||||||||||||||||||
Full Title: A Phase 1b/2, open-label dose escalation with expansion study of GB5121 in adult patients with relapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymp... | ||||||||||||||||||
Medical condition: Relapsed/refractory primary or secondary central nervous system lymphoma or primary vitreoretinal lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-001055-38 | Sponsor Protocol Number: IELSG20 | Start Date*: 2003-11-28 | |||||||||||
Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG | |||||||||||||
Full Title: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE, ALONE OR ASSOCIATED WITH HIGHDOSE CYTARABINE, FOLLOWED BY RESPONSE- AND AGE-TAILORED RADIOTHERAPY FOR IMMUNOCOMPETENT ... | |||||||||||||
Medical condition: primary chemotherapy of primary central nervous system lymphoma with high dose cytarabine plus methotrexate | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001306-33 | Sponsor Protocol Number: PQR309-005 | Start Date*: 2017-03-08 | |||||||||||
Sponsor Name:PIQUR Therapeutics AG | |||||||||||||
Full Title: Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma | |||||||||||||
Medical condition: Relapsed or refractory primary CNS lymphoma (PCNSL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) BE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003235-29 | Sponsor Protocol Number: CC-99282-NHL-001 | Start Date*: 2022-01-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||||||||||||||||||||||
Full Title: A PHASE I/II, MULTI-CENTER, OPENLABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH ANTILYMPH... | |||||||||||||||||||||||||||||||||
Medical condition: Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central ner... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Ongoing) AT (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000056-23 | Sponsor Protocol Number: NL52204.041.15 | Start Date*: 2015-08-19 |
Sponsor Name:UMC Utrecht | ||
Full Title: 89Zr-rituximab PET/CT for detection of central nervous system lymphoma | ||
Medical condition: central nervous system localized malignant lymphoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002241-22 | Sponsor Protocol Number: CA186-107 | Start Date*: 2014-12-26 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodg... | ||||||||||||||||||
Medical condition: Advanced Solid Tumors Advanced B-cell NHL | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000227-24 | Sponsor Protocol Number: RG_13-320 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma | |||||||||||||
Medical condition: Relapsed or refractory primary central neurvous system lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007645-31 | Sponsor Protocol Number: 00591 | Start Date*: 2009-06-23 | |||||||||||
Sponsor Name:University Medical Center Freiburg | |||||||||||||
Full Title: Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie - PRIMAIN-Studie - | |||||||||||||
Medical condition: Patients with primary CNS Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000894-19 | Sponsor Protocol Number: CA209-647 | Start Date*: 2016-09-28 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL) | ||||||||||||||||||
Medical condition: Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) FR (Completed) DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001532-11 | Sponsor Protocol Number: 01apr2014 | Start Date*: 2014-09-11 |
Sponsor Name:Ospedale San Raffaele | ||
Full Title: MONO-INSTITUTIONAL PHASE II TRIAL ADDRESSING TOLERABILITY AND ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY PRECEDED BY BLOOD-BRAIN BARRIER PERMEABILIZATION BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RE... | ||
Medical condition: Primary non-Hodgkin lymphoma in the central nervous system relapse / refractory | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003116-12 | Sponsor Protocol Number: IELSG45 | Start Date*: 2019-11-01 | |||||||||||
Sponsor Name:International Extranodal Lymphoma Study Group - IELSG | |||||||||||||
Full Title: RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial) | |||||||||||||
Medical condition: Patients with newly diagnosed primary central nervous system lymphoma with age ≥70 years old | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) FI (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003031-19 | Sponsor Protocol Number: IELSG42 | Start Date*: 2014-12-15 |
Sponsor Name:IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP) | ||
Full Title: An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by auto... | ||
Medical condition: systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001768-31 | Sponsor Protocol Number: ZENO-01 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
Medical condition: MALT Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005297-10 | Sponsor Protocol Number: DCL-16-001 | Start Date*: 2021-05-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Cellectar Biosciences, Inc. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobu... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Part A: MM (multiple myeloma), CLL/SLL(chronic lymphocytic leukemia/small lymphocytic lymphoma), LPL/WM(lymphoplasmacytic lymphoma/ Waldenstrom's Macroglobulinemia), MZL(marginal zone lymphoma), MC... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) GR (Ongoing) FR (Ongoing) ES (Ongoing) FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003786-17 | Sponsor Protocol Number: IC2012-08 | Start Date*: 2013-03-29 | |||||||||||
Sponsor Name:INSTITUT CURIE | |||||||||||||
Full Title: Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL) - “Proof of concept” | |||||||||||||
Medical condition: Primary central nervous system or Intra ocular lymphoma in relapse or refractory to previous treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000106-38 | Sponsor Protocol Number: JCAR017-BCM-001 | Start Date*: 2018-06-14 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCEND WORLD) | ||||||||||||||||||
Medical condition: Aggressive B-cell Non Hodgkin Lymphoma (B-NHL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) FI (Completed) ES (Restarted) DE (Completed) AT (Completed) NL (Ongoing) GB (Temporarily Halted) IT (Restarted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004289-42 | Sponsor Protocol Number: ZENO-06021957 | Start Date*: 2008-03-20 | |||||||||||
Sponsor Name:National and Kapodistrian University of Athens | |||||||||||||
Full Title: 90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
Medical condition: extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004014-17 | Sponsor Protocol Number: FIL_GA101_DHAP | Start Date*: 2014-08-04 | |||||||||||
Sponsor Name:Fondazione Italiana Linfomi ONLUS | |||||||||||||
Full Title: Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem cell transplantatio... | |||||||||||||
Medical condition: Young patients with DLBCL who failed or relapsed after one previous chemotherapy regimen. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.